GSK cuts 40% of China sales reps after bribery scandal
Shanghai
GLAXOSMITHKLINE Plc has cut 40 per cent of its sales reps in China and axed some units as it eyes a return to growth in 2016, after sales plunged during a bribery scandal that landed it with a record US$490 million fine in 2014.
The British firm is gambling on a new, cleaner image to reboot its performance and reputation with doctors and consumers, China head Herve Gisserot told Reuters at the group's Shanghai headquarters.
TRENDING NOW
Yeo’s, Tiger Beer and now Gardenia – flight of food manufacturing from Singapore might be just as planned
Xi Jinping has just rewritten the rules of US-China rivalry
Brewing success: How three brothers turned Brewerkz Group’s fortunes around
Singapore developer in limbo after Timor-Leste scraps major township project